CVS Health reaffirms FY2023 GAAP EPS $6.53-$6.75, Adjusted EPS $8.50-$8.70, CFO $12.5B-$13.5B

CVS HEALTH Corp

Reaffirms FY2023 GAAP diluted EPS range $6.53–$6.75, unchanged from prior guidance.
Reaffirms FY2023 Adjusted EPS range $8.50–$8.70, unchanged.
Reaffirms FY2023 cash flow from operations guidance $12.5B–$13.5B.
Management to present at investor meeting on September 12, 2023; webcast available.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.